Form 4 for HUMA Humacyte, Inc.
Accepted 2024-11-21 00:00:00 ET · period of report 2024-11-19 · accession 0001818382-24-000213 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-11-21 | 2024-11-19 | HUMA | Dougan Brady W | Dir | P - Purchase | $4.44 | +1,797 | 243.9K | +0.7% | +$7,979 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-19 | P | A | 1,797 | $4.44 | 243,851 | I By spouse | — | — | (F1) This purchase by the Reporting Person's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person's spouse has paid the Issuer $8,778.23, representing the full amount of profit realized in connection with this purchase. (F2) The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.435 to $4.4352. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |